do you attribute the almost 20% decline in fmi over last 5 days to disappointment over the number of tests performed in 3rd qtr and/or projections of tests moving forward?
and on enta..with approval baked into the price,what will it take to see a pop in the stock.is it a matter of the analysts upgrading there expectations of the abbv/enta HCV market share from 15-20% to 35-40%?
And if they don't get a 12 week label for cirrhotic patients do you think we will see a downturn in stock price,or is that news not expected to occur?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.